CD163 and neoplasm: Interestingly, immunostaining of melanoma samples from a patient who developed resistance to nivolumab revealed higher expression of IL-34, compared to the primary tumor, which positively correlated with an increased frequency of CD163+ TAMs and poor prognosis [127].